Sacituzumab govitecan in Japanese participants with HR+/HER2− metastatic breast cancer: primary results from the phase II ASCENT-J02 study

Although the primary endpoint (ORR by IRC) was not met (P > .025), overall efficacy results were generally similar to TROPiCS-02, supporting access to SG in Japanese patients with HR+/HER2- mBC. Safety was consistent with the known and manageable SG safety profile.